OncoMatch/Clinical Trials/NCT06268652
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Is NCT06268652 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Gemcitabine and Capecitabine for breast cancer.
Treatment: Gemcitabine · Capecitabine · Vinorelbine · Eribulin — This multicenter, open-label, randomized phase III trial is designed to study the efficacy and safety of organoid-guided personalized treatment （OGPT）versus treatment of physician's choice (TPC) in previously treated refractory breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Breast Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
WBC ≥3 × 10^9/L; ANC ≥1.5 × 10^9/L; PLT ≥100 × 10^9/L; Hgb ≥8g/dL
Kidney function
serum creatinine clearance (CG formula) > 30 mL/min
Liver function
AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN (no liver invasion) or ≤ 5 × ULN (with liver invasion); total bilirubin (TBIL) ≤ ULN
Cardiac function
No serious organ (main organ: heart, lung, liver, kidney) functional abnormalities (refer to respective standards); Exclude NYHA Class III or IV heart failure, poorly controlled coronary artery disease or arrhythmia, or history of myocardial infarction within 6 months
No serious organ (main organ: heart, lung, liver, kidney) functional abnormalities (refer to respective standards); Routine blood test: white blood cells (WBC) ≥3 × 10^9/L; absolute neutrophil count (ANC) ≥1.5 × 10^9/L; platelets (PLT) ≥100 × 10^9/L; hemoglobin (Hgb) ≥8g /dL; Blood biochemical indicators: AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN (no liver invasion) or ≤ 5 × ULN (with liver invasion); total bilirubin (TBIL) ≤ ULN; serum creatinine clearance (CG formula) > 30 mL/min; Coagulation function: PT, INR ≤ 1.5 × ULN (unless warfarin is being used for anticoagulation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06268652 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages